natgillin/translations-raw huggingface dataset:
Reducer kun ribavirin daglig dosis (se note 1) hvis:
Reduce only ribavirin daily dose (see note 1) if:
Reducer kun ribavirin daglig dosis (se note 1), hvis:
Reduce only ribavirin daily dose (see note 1), if:
Reducer kun ViraferonPeg-dosis (se note 2), hvis:
Reduce only ViraferonPeg dose (see note 2) if:
Reducer med 1 dosisniveau i forhold til foregående niveau
Reduce by 1 dose level from previous level
Reducer ONIVYDE-dosis til 40 mg/m2 5-FU-dosisændring som i skema 1
Reduce ONIVYDE dose to 40 mg/m2 5-FU dose modification as in Table 1
Reducer ONIVYDE-dosis til 50 mg/m2 5-FU-dosisændring som i skema 1
Reduce ONIVYDE dose to 50 mg/m2 5-FU dose modification as in Table 1
Reducer ONIVYDE-dosis til 50 mg/m2 Reducer 5-FU-dosis med yderligere 25 % (1.350 mg/m2)
Reduce ONIVYDE dose to 50 mg/m2 Reduce 5-FU dose by an additional 25% (1350 mg/m2).
Reducer ONIVYDE-dosis til 60 mg/m2 Reducer 5-FU-dosis med 25 % (1.800 mg/m2)
Reduce ONIVYDE dose to 60 mg/m2 Reduce 5-FU dose by 25% (1800 mg/m2)
Reducer Pegasys til 135/90/45 mikrogram
Reduce Pegasys to 135/90/45 micrograms
Reducer Temozolomid med 1 dosistrina
Reduce TMZ by 1 dose levela
Reducer VELCADE til 1,0 mg/m2 eller
Reduce VELCADE to 1.0 mg/m2 or
Reducer ViraferonPeg til halv dosis, hvis:
Reduce ViraferonPeg to one-half dose if:
reducere risikoen for nye intramammære infektioner i goldperioden, begrænse dyrenes ubehag.
reduce the risk of new intramammary infections during the dry period, reduce discomfort.
Reducere sygdomstegn og symptomer på Deres sygdom.
Reduce the signs and symptoms of your disease.
Reducere tegn og symptomer på din sygdom
Reduce the signs and symptoms of your disease
Reducere tegn og symptomer på din sygdom
Reduce the signs and symptoms of your disease,
reducere tegn og symptomer på din sygdom forbedre din fysiske funktionsevne.
reduce the signs and symptoms of your disease, improve your physical function.
Reducerede ciclosporin-, mycophenolatmofetil- og tacrolimus-niveauer er blevet rapporteret hos transplantationspatienter co-administreret sevelamerhydrochlorid uden kliniske konsekvenser (dvs. organafstødning).
Reduced levels of ciclosporin, mycophenolate mofetil and tacrolimus have been reported in transplant patients when coadministered with sevelamer hydrochloride without any clinical consequences (i.e graft rejection).
Reducerede dosisniveauer (> 75 år): Startdosis: 20 mg; dosisniveau -1: 12 mg; dosisniveau -2: 8 mg på dag 1, 8, 15 og 22 i hver behandlingscyklus på 28 dage.
Dose reduction levels (> 75 years of age): Starting dose 20 mg; dose level -1 12 mg; dose level-2 8 mg on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
Reducerede dosisniveauer (≤ 75 år): Startdosis: 40 mg; dosisniveau -1: 20 mg; dosisniveau -2: 10 mg på dag 1, 8, 15 og 22 i hver behandlingscyklus på 28 dage.
Dose reduction levels (≤ 75 years of age): Starting dose 40 mg; dose level -1 20 mg; dose level-2 10 mg on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
Reducerede niveauer af ciclosporin, mycophenolatmofetil og tacrolimus er rapporteret hos transplantationspatienter ved samtidig indgivelse af sevelamer hydrochlorid, uden kliniske konsekvenser (f.eks. rejektion af transplantat).
Reduced levels of ciclosporin, mycophenolate mofetil and tacrolimus have been reported in transplant patients when co-administered with sevelamer hydrochloride without any clinical consequences (e.g., graft rejection).
Reducerede niveauer af ciclosporin, mycophenolatmofetil og tacrolimus er rapporteret hos transplantationspatienter ved samtidig indgivelse af sevelamerhydrochlorid, uden kliniske konsekvenser (f.eks. rejektion af transplantat).
Reduced levels of ciclosporin, mycophenolate mofetil and tacrolimus have been reported in transplant patients when co-administered with sevelamer hydrochloride without any clinical consequences (e.g., graft rejection).
reducerede niveauer af hvide blodlegemer (som bekæmper infektion) og røde blodlegemer (som transporterer ilt rundt i kroppen).
reduced levels of white blood cells (which fight infection) and red blood cells (which carry oxygen around the body)
reducerede testosteronniveauer,
reduced testosterone levels
Reducerede værdier for blodundersøgelser for hormonet kortisol
Decreased values for blood investigations for the hormone cortisol
reduceres med 50%, dvs.
reduced by 50 %, i.e., to 300 mg
reduceres til 300 mg QD.
300 mg QD.
reduceres til en tredjedel af det
reduced to a third of the
Reduceret
Reduced dose
Reduceret absolut neutrofilværdi, forhøjet alkalisk fosfatase, fald i albumin, forhøjet blodamylase, forhøjet bilirubin i blodet, forhøjet kolesteroltal, stigning i serumkreatinin, stigning i blodsukker, stigning i karbamidkvælstof, forhøjet kreatinfosfokinase, stigning i fasteblodsukker, sukker i urinen, stigning i HDL, forhøjet international normaliseret ratio (INR), stigning i LDL, fald i antal blodplader, positiv test for røde blodlegemer i urinen, øget abdominalomfang, vægtøgning, fald i antal hvide blodlegemer.
absolute neutrophil count decreased, alkaline phosphatase increased, blood albumin decreased, blood amylase increased, blood bilirubin increased, blood cholesterol increased, blood creatinine increased, blood glucose increased, blood urea nitrogen increased, creatine phosphokinase increased, fasting blood glucose increased, glucose urine present, high density lipoprotein increased, international normalised ratio increased, low density lipoprotein increased, platelet count decreased, red blood cells urine positive, waist circumference increased, weight increased, white blood cell count decreased
Reduceret absorption af phenylbutyrat ved pancreasinsufficiens eller intestinal malabsorption
Reduced phenylbutyrate absorption in pancreatic insufficiency or intestinal malabsorption
Reduceret aktivitet forekom med samme hyppighed hos både hunde i kontrolgruppen og hunde behandlet med 3 gange den maksimale anbefalede dosis.
Decreased activity was seen at the same frequency in both control and dogs treated with 3 times the maximum recommended dose.
reduceret antal blodceller (neutropeni eller lymfopeni, thrombocytopeni)
reduced number of blood cells (neutropenia or lymphopenia, thrombocytopenia)
Reduceret antal hvide blodceller (<3000/mm3) 
White blood cell count decreased (<3000/mm³) 
reduceret antal hvide blodlegemer, hævede lymfekirtler (lymfadenopati)
reduced number of white blood cells, swollen lymph glands (lymphadenopathy)
Reduceret appetit
Decreased appetite
Reduceret berøringssans eller fornemmelse
Reduced sense of touch or sensation
Reduceret blodglukose (< 55 mg/dl) x
Blood glucose decreased (<55 mg/dl) 
Reduceret blodglukose (<55 mg/dl) x
Blood glucose decreased (<55 mg/dl) 
Reduceret delt dosis
Reduced split-dose
Reduceret dosis (50 %)
Reduced dose (50%)
Reduceret dosis (75 %)
Reduced dose (75%)
Reduceret dosis (én gang dagligt)
Reduced dose (once daily)
Reduceret ejektionsfraktion
Ejection fraction decreased
Reduceret eller helt manglende -galaktosidase-aktivitet medfører akkumulation af GL-3 i lysosomerne af mange celletyper, herunder endotel- og parenkymale celler, hvilket i sidste ende forårsager livstruende, klinisk forværring som følge af nyre-, hjerte- og cerebrovaskulære komplikationer.
Reduced or absent - galactosidase activity results in the accumulation of GL-3 in the lysosomes of many cell types including the endothelial and parenchymal cells, ultimately leading to life-threatening clinical deteriorations as a result of renal, cardiac and cerebrovascular complications.
Reduceret eller ikke eksisterende -L-iduronidase-aktivitet medfører akkumulation af GAG, dermatansulfat og heparansulfat i mange celletyper og væv.
Reduced or absent -L-iduronidase activity results in the accumulation of the GAGs, dermatan sulfate and heparan sulfate in many cell types and tissues.
Reduceret følelse
Reduced sensation
Reduceret følsomhed over for echinocandiner har været associeret med mutationer i Fks1-genet, som koder for en større subunit i glukansyntase.
Reduced susceptibility to echinocandins has been associated with mutations in the Fks1 and Fks2 genes coding for a major subunit of glucan synthase.
reduceret gastrointestinal motilitet
Decreased gastrointestinal motility
Reduceret hæmoglobin (iltbærende pigment i blodet) og leukocytter (hvide blodlegemer).
Decrease in haemoglobin (oxygen-carrying pigment in blood) and leukocytes (white blood cells).
Reduceret hæmoglobin Nedsat antal hvide blodlegemer
Haemoglobin decreased White blood cell count decreased
Reduceret iltmætning
Oxygen saturation decreased
Reduceret iltmætning Forhøjet hjertefrekvens
Periorbital edema Livedo reticularis Lacrimation increased Rash
Reduceret infusionsvolumen (rekonstitueret Cancidas overført til 100 ml) endelig koncentration
Reduced volume infusion (reconstituted CANCIDAS added to 100 ml) final concentration
reduceret lokoregional kontrol hos patienter med fremskreden hoved- og halscancer, som får strålebehandling, når stofferne administreres for at opnå en hæmoglobinkoncentration, som er højere end 14 g/dl (8,7 mmol/l),
decreased locoregional control in patients with advanced head and neck cancer receiving radiation therapy when administered to achieve a haemoglobin concentration level of greater than 14 g/dl (8.7 mmol/l),
reduceret oxygenmætning
oxygen saturation decreased
reduceret penisstørrelse
penis size reduced
Reduceret penisstørrelse Trombose i penil vene Ødem i skrotum Smerter i skrotum
Penile size reduced Penile vein thrombosis Scrotal oedema Scrotal pain
Reduceret respons for akustisk forskrækkelse ses hos juvenile rotter 1-2 uger efter doser > 2 gange højere end terapeutisk dosis hos mennesker.
Reduced acoustic startle response was observed in juvenile rats 1 – 2 weeks after exposure at > 2 times the human therapeutic exposure.
Reduceret respons for akustisk forskrækkelse ses hos juvenile rotter 1-2 uger efter doser >2 gange højere end terapeutisk dosis hos mennesker.
Reduced acoustic startle response was observed in juvenile rats 1-2 weeks after exposure at >2 times the human therapeutic exposure.
Reduceret score (forbedring)
Decreased score (Improvement)
reduceret smertetærskel
decreased sensitivity to pain
Reduceret testosteronniveau†
Reduced testosterone levels
Reduceret tolerance for skarpt lys
Decreased tolerability of the eyes for bright light
reduceret, og
metabolite exposure increased.
Reducering af hydrokodon-
A reduction of
Reducér Bortezomib Hospira til 0,7 mg/m2 i den første behandlingscyklus.
Reduce Bortezomib Hospira to 0.7 mg/m2 in the first treatment cycle.
Reducér pravastatin-
Pravastatin 10
Reducér pravastatin-dosen
Reduce pravastatin dose by
Reducér til 0,5 ME/kg/dag (5 mikrogam/kg/dag)
Reduce to 0.5 MU/kg/day (5 micrograms/kg/day)
reduktasehæmmeren.
inhibitor.
Reduktion af aggressive og seksuelle (montage) adfærd kan forventes fra 1 til 2 uger efter anden vaccination.
Reduction of aggressive and sexual (mounting) behaviours can expected from 1 to 2 weeks post second vaccination.
Reduktion af antallet af hvide blodlegemer.
Reduction of the number of white blood cells.
Reduktion af bicarbonat i blodet
Blood bicarbonate decreased
Reduktion af blodtryk med 0,5 mg/kg (lav), 1,5 mg/kg (middel) og 4,5 mg/kg (høj) mål-titrerede doser af irbesartan evalueredes, over en periode på 3 uger, hos 318 børn og unge eller børn med hypertension eller i risiko for at udvikle hypertension (diabetes, familiær disposition for hypertension) i aldersgruppen 6 til 16 år.
Reduction of blood pressure with 0.5 mg/kg (low), 1.5 mg/kg (medium) and 4.5 mg/kg (high) target titrated doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family history of hypertension) children and adolescents aged 6 to 16 years over a three week period.
Reduktion af clarithromycindosis kan
A dose reduction of clarithromycin
Reduktion af dalbavancindosis er ikke nødvendig hos patienter med let nedsat leverfunktion (Child- Pugh A).
No dose adjustment of dalbavancin is recommended for patients with mild hepatic impairment (Child-Pugh A).
Reduktion af den 6-minutters gangtest på grund af PH
Decrease in 6MWD due to PH
Reduktion af den antihypertensive virkning.
Reduction of the antihypertensive effect.
Reduktion af det diastoliske blodtryk til < 90 mmHg sås hos henholdsvis 71,6%, 74,8%, 82,1% 85,3% af patienterne.
The reduction in diastolic blood pressure <90 mmHg was achieved in 71.6 %, 74.8 %, 82.1 %, 85.3% of patients respectively.
Reduktion af diarre forårsaget af diagnosticeret Cryptosporidium parvum.
Reduction of diarrhoea due to diagnosed Cryptosporidium parvum.
Reduktion af dosis eller seponering af TMZ under monoterapi
TMZ dose reduction or discontinuation during monotherapy treatment
Reduktion af dosis kunne nedsætte eller stoppe progressionen af miltforstørrelsen, men hos 3 % af patienterne blev det nødvendigt med splenektomi.
Dose reductions were noted to slow or stop the progression of splenic enlargement, and in 3% of patients a splenectomy was required.
reduktion af dødelighed :
a reduction of mortality :
reduktion af dødelighed : hos anæmiske katte med en dødelighed på ca.
a reduction of mortality :
Reduktion af forhøjet intraokulært tryk (IOP) ved kronisk åbenvinklet glaukom og okulær hypertension hos voksne (som monoterapi eller som supplerende behandling til beta-blokkere).
Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as monotherapy or as adjunctive therapy to beta-blockers).
Reduktion af gennemsnitlig
Reduction of the mean fasting blood
Reduktion af gennemsnitlig faste
Reduction of the mean fasting blood
Reduktion af gennemsnittet af morgen og aften to-timers
Reduction of the mean of combined morning / evening two-hour postprandial
Reduktion af gennemsnittet af morgen og aften to-timers postprandial
Reduction of the mean of combined morning / evening two-hour postprandial
reduktion af hepatisk glucoseproduktion gennem hæmning af glukoneogenese og glycogenolyse,
reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis,
Reduktion af hyperkalcæmi hos patienter med:
Reduction of hypercalcaemia in patients with:
Reduktion af indinavirdosis til 600 mg hver 8. time bør overvejes.
Dose reduction of Indinavir to 600 mg every 8 hours should be considered.
Reduktion af indinavirkoncentrationen på grund af induktion af lægemiddelmetabolisering og/eller perikons transportproteiner.
Reduction in indinavir concentrations due to induction of medicinal product metabolising and/or transport proteins by St. John’s wort.
Reduktion af inflammatoriske læsioner og forebyggelse af forværring af abscesser og suppurerende fistler blev evalueret ved hjælp af ”Hidradenitis Suppurativa Clinical Response” (HiSCR; mindst 50% reduktion i det totale antal abscesser og inflammatoriske noduli og uden stigning i antallet af abscesser og antallet af suppurerende fistler i forhold til baseline).
Reduction of inflammatory lesions and prevention of worsening of abscesses and draining fistulas was assessed using Hidradenitis Suppurativa Clinical Response (HiSCR; at least a 50% reduction in total abscess and inflammatory nodule count with no increase in abscess count and no increase in draining fistula count relative to Baseline).
Reduktion af inhalationer/dag af anfalds-medicin vs. baseline
Reduction in puffs/day of rescue medication use vs. baseline
Reduktion af Kalydeco-dosis til 150 mg to gange om ugen anbefales ved administration sammen med potente CYP3A-hæmmere såsom ketoconazol, itraconazol, posaconazol, voriconazol, telithromycin og clarithromycin.
A reduction of the Kalydeco dose to 150 mg twice a week is recommended for co-administration with strong CYP3A inhibitors, such as ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin and clarithromycin.
Reduktion af Kalydeco-dosis til 150 mg én gang dagligt anbefales til patienter, der samtidig behandles med moderate CYP3A-hæmmere såsom fluconazol og erythromycin.
A reduction of the Kalydeco dose to 150 mg once daily is recommended for patients taking concomitant moderate CYP3A inhibitors, such as fluconazole and erythromycin.
Reduktion af Kalydeco-dosis til som anbefalet ovenfor, men administreret en gang dagligt anbefales til patienter, der samtidig behandles med moderate CYP3A-hæmmere såsom fluconazol og erythromycin.
A reduction of the Kalydeco dose as above recommended, but administered once daily is recommended for patients taking concomitant moderate CYP3A inhibitors, such as fluconazole and erythromycin.
Reduktion af LVEF/dysfunktion af venstre ventrikel
LVEF reduction/Left ventricular dysfunction
Reduktion af microfilariae (D. repens)
Reduction of microfilariae (skin worm) (D. repens)
Reduktion af plasmakoncentration- en af bupropion er sandsynligt på grund af induktionen af CYP2B6 og UGT-aktivitet af RTV.
The reduction of bupropion plasma levels is likely due to induction of CYP2B6 and UGT activity by RTV
Reduktion af post-operative smerter (over en periode på 24 timer): Enkelt intravenøs eller subcutan injektion med en dosis på 0,2 mg meloxicam/kg kropsvægt (dvs.
Reduction of post-operative pain (over a period of 24 hours): Single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg bodyweight (i.e.
Reduktion af post-operative smerter efter ovariehysterektomi og mindre omfattende bløddelskirurgi.
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.
Reduktion af post-operative smerter efter ovariohysterektomi og mindre kirurgiske indgreb i blødt væv.
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.
Reduktion af postoperative smerter (i et tidsrum af 24 timer):
Reduction of post-operative pain (over a period of 24 hours):
Reduktion af postoperative smerter efter ovariehysterektomi og mindre omfattende bløddelskirurgi.
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.
Reduktion af postoperative smerter:
Reduction of post-operative pain
Reduktion af proteinuria associeret med kronisk nyresygdom (CKD) hos katte.
Reduction of proteinuria associated with chronic kidney disease (CKD) in cats.
Reduktion af QT-intervallet
QT shortening
Reduktion af ribavirindosis versus erythropoietin i behandlingen af anæmi hos tidligere ubehandlede personer
Use of ribavirin dose reduction versus erythropoietin in the management of anaemia in previously untreated subjects
reduktion af rifabutin-dosis til
dosage reduction of rifabutin to
reduktion af rifabutindosis til
reduction of rifabutin to 150 mg
reduktion af rifabutindosis til 150
to rifabutin.
Reduktion af risikoen for progression var 32,1 % og blev associeret med en signifikant længere TTP (p = 0,0004) til fordel for TCF-armen.
The risk reduction of progression was 32.1% and was associated with a significantly longer TTP (p = 0.0004) in favor of the TCF arm.
Reduktion af sværhedsgrad-efter-varighed af zosterassocierede smerter hos vaccinerede patienter, som fik herpes zoster
Reduction of zoster pain severity-by-duration in vaccinated individuals who developed zoster
Reduktion af tocilizumab-dosis på grund af laboratorieanormaliteter er ikke blevet undersøgt hos patienter med pJIA.
Reduction of tocilizumab dose due to laboratory abnormalities has not been studied in pJIA patients.
Reduktion af varigheden af neutropeni og forekomsten af febril neutropeni hos voksne patienter i behandling med cytotoksisk kemoterapi for malignitet (med undtagelse af kronisk myeloid leukæmi og myelodysplastiske syndromer).
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Reduktion af venstre ventrikels ejektionsfraktion (LVEF)/dysfunktion af venstre ventrikel
Left ventricular ejection fraction (LVEF) reduction/Left ventricular dysfunction
Reduktion af venstre ventrikels uddrivningsfraktion (LVEF)/dysfunktion af venstre ventrikel
Left ventricular ejection fraction (LVEF) reduction/Left ventricular dysfunction
Reduktion af vitamin B12-absorption og laktatacidose*
Decrease of vitamin B12 absorption and lactic acidosis
Reduktion eller seponering af TMZ-dosis under monoterapi
TMZ dose reduction or discontinuation during monotherapy treatment
Reduktion eller øgning af phenytoins plasmakoncen- trationer, phenobarbital og andre krampestillende lægemidler, som er substrater for CYP-isozymer, er mulig med efavirenz.
There is a potential for reduction or increase in the plasma concentrations of phenytoin, phenobarbital and other anticonvulsants that are substrates of CYP isozymes with efavirenz.
Reduktion fra baseline i AUC0:30-4:30 t for plasmaglucose efter et testmåltid var: -12,61 t∙mmol/l (-227,25 t∙mg/dl) i lixisenatidgruppen og -4,04 t∙mmol/l (- 72,83 t∙mg/dl) i liraglutid-gruppen.
Reduction from baseline in the AUC0:30-4:30 h of plasma glucose after a test meal was: -12.61 h*mmol/L (-227.25 h*mg/dl) in the lixisenatide group and -4.04 h*mmol/L (-72.83 h*mg/dl) in the liraglutide group.
Reduktion fra baseline i AUC0:30-4:30 t for plasmaglucose efter et testmåltid var: -12,61 t∙mmol/l (-227,25 t∙mg/dl) i lixisenatidgruppen og -4,04 t∙mmol/l (- 72,83 t∙mg/dl) i liraglutid-gruppen.
Reduction from baseline in the AUC0:30-4:30 h of plasma glucose after a test-meal was: -12.61 h*mmol/L (-227.25 h*mg/dl) in the lixisenatide group and -4.04 h*mmol/L (-72.83 h*mg/dl) in the liraglutide group.
reduktion i
11.8
reduktion i antallet af blodplader kan kendes ved at du let får blå mærker eller bløder (trombocytopeni)
reduction in the number of blood platelets, characterised by easy bruising or bleeding (thrombocytopenia)
reduktion i antallet af hvide blodceller i blodet og i antallet af celler, der hjælper blodet med at størkne,
reduction in the number of white cells in the blood, and cells that help the blood clot,
reduktion i antallet af hvide blodlegemer (leukopeni)
reduction in the number of white blood cells (leucopenia)
reduktion i antallet af røde blodlegemer (anæmi)
reduction in the number of red blood cells (anaemia)
reduktion i antallet af røde blodlegemer (anæmi), ses som bleg hud, svaghed eller åndenød
reduction of red blood cells (anaemia) seen as pale skin, weakness or breathlessness
reduktion i antallet af røde blodlegemer (der kan medføre træthed, åndenød, svimmelhed), nedsat antal neutrofiler (der gør barnet mere modtagelig for forskellige infektioner),
decreases in the number of red blood cells (that may cause fatigue, shortness of breath, dizziness), decrease in neutrophils (that make you more susceptible to different infections),
Reduktion i antallet af røde blodlegemer eller hvide blodlegemer (se ovenfor)
Reduction in the number of red blood cells and or white blood cells (see above)
reduktion i antallet af røde blodlegemer og/eller hvide blodlegemer (se ovenfor)
reduction in the number of red blood cells and/or white blood cells (see above)
reduktion i antallet af røde blodlegemer, som kan gøre din hud bleg og gøre dig stakåndet og svag gulsot (gulfarvning af huden og øjnene), dette er kun indberettet hos spædbørn.
reduction in red blood cells which may turn your skin pale and make you breathless and weak, jaundice (yellowing of the skin and eyes), this has only been reported in infants.
Reduktion i CDAI ≥ 25 % og ≥ 70 point.
Reduction in CDAI ≥25% and ≥70 points.
reduktion i eksponering
reduction in exposure as
Reduktion i forekomsten af gastroenteritis som følge af rotavirus gennem en hel sæson efter vaccination (RotaTeq n=2.834) % [95 % CI]
Reduction in incidence of RV gastroenteritis through one full season post-vaccination (RotaTeq n=2,834) (% [95 % CI])
Reduktion i HS-relateret hudsmerte blev evalueret ved hjælp af en numerisk vurderingsskala hos patienter, som gik ind i studiet med start- baseline score på 3 eller højere på en skala med 11 trin.
Reduction in HS-related skin pain was assessed using a Numeric Rating Scale in patients who entered the study with an initial baseline score of 3 or greater on a 11 point scale.
Reduktion i Itch NRS på ≥ 4b
Itch NRS reduction ≥ 4b
Reduktion i kalorieindtagelsen ved parenteral ernæring
Reduction in parenteral nutrition calories
reduktion i kliniske tegn i løbet af den symptomatiske fase (4 måneder)
a reduction of clinical signs during the symptomatic phase (4 months)